Compound Detail
CHEMBL59990
MAFOSFAMIDE 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL59990 |
| Name | MAFOSFAMIDE |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | PBUUPFTVAPUWDE-UHFFFAOYSA-N |
1
Targets
1
Activities
1
Assay Types
0
PK Parameters
1
Publications
2
Known Names
5
Indications
Molecular Properties
401.3
MW (Da)
1.83
ALogP
5
HBA
2
HBD
95.9
PSA (Ų)
0.34
QED
0
Ro5 Violations
9
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Racemic |
Indications
Central Nervous System Neoplasms Leukemia Lymphoma Meningeal Neoplasms Meningeal Neoplasms
Activity Summary
IC50 1 meas. best 4.38
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| L1210 CHEMBL386 | IC50 | 4.38 | 4.38 | 42000.0 | 1 |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| L1210 | IC50 | = | 42000.0 | nM | 4.38 | Concentration required to reduce the viability of L1210 cells by 50% after 1-h i... | 1992116 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 1992116 | 10.1021/jm00105a030 | L1210 | 1 |
Data from ChEMBL 36 via Core Engine